Trials / Completed
CompletedNCT03981705
Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 8 (actual)
- Sponsor
- Masonic Cancer Center, University of Minnesota · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a feasibility study to gain preliminary information regarding whether breast imaging with or without a core needle biopsy after neoadjuvant chemotherapy (NAC) but before surgery can accurately predict complete pathologic response (pCR) in women with triple negative or HER2- positive breast cancer. pCR is defined as having no residual invasive breast cancer or ductal carcinoma in situ.
Conditions
- TN ER-/PR-/HER2- Breast Cancer
- Triple Negative Breast Cancer
- HER2-positive Breast Cancer
- ERany/PRany/HER2+ Breast Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Standard Trimodality Breast Imaging | Standard breast imaging with or without core needle biopsy after neoadjuvant chemotherapy (NAC). |
Timeline
- Start date
- 2019-08-08
- Primary completion
- 2024-02-19
- Completion
- 2024-11-26
- First posted
- 2019-06-11
- Last updated
- 2024-12-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03981705. Inclusion in this directory is not an endorsement.